Compass Therapeutics (NASDAQ:CMPX) Announces Earnings Results, Misses Estimates By $0.03 EPS

Compass Therapeutics (NASDAQ:CMPX) announced its earnings results on Monday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03), FiscalAI reports.

Compass Therapeutics Price Performance

CMPX stock opened at $0.76 on Monday. The stock has a market capitalization of $136.65 million, a P/E ratio of -1.90 and a beta of 1.06. Compass Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $6.88. The business has a 50-day moving average of $1.29 and a 200-day moving average of $3.10.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on CMPX. Wall Street Zen cut Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Citizens Jmp lowered their price target on shares of Compass Therapeutics to $4.00 and set a “market outperform” rating on the stock in a report on Wednesday, September 23rd. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. Guggenheim reduced their price objective on shares of Compass Therapeutics to $4.00 and set a “buy” rating for the company in a report on Wednesday, September 23rd. Finally, Wedbush set a $4.00 target price on shares of Compass Therapeutics in a research report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Compass Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $10.25.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.